Theolytics Ltd. Asset Profile

= Subscriber Access Only

You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.

Year established

2017

Location

Oxford UK

Primary Industry

Biotechnology

About

Founded in 2017 and based in Oxford, UK, Theolytics Limited operates as a biotechnology company. The company was founded by its CSO, Margaret Duffy. In August 2024, Theolytics Ltd. raised GBP 2 million in grant funding from new investor Innovate UK. As of 2024, the company is led by its CEO, Charlotte Casebourne Stock. Theolytics develops and offers next-generation oncolytic viral therapies. The company's lead product candidate, THEO-260, is a next-generation oncolytic adenovirus for the treatment of ovarian cancer. The company plans to use the grant funding raised in August 2024 to support its Phase 1 clinical trial of THEO-260 and to establish the recommended dose for Phase 2.

Current Investors

Oxford Sciences Enterprises, Epidarex Capital, Taiho Ventures

Request a demo to show more

Primary Industry

Biotechnology

Sub Industries

Biopharmaceuticals, Oncology/Cancer Treatment, Pharmaceutical Research & Development

Website

www.theolytics.com

Company Stage

Series A

Total Amount Raised

Subscriber access only

Time to go Pro

Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.